logo
ENFRع
#

Latest news with #MorganStanleyInvestmentManagement

Morgan Stanley China A Share Fund, Inc. Announces Advisory Fee Reduction and Update on Performance-Related Conditional Tender Offer
Morgan Stanley China A Share Fund, Inc. Announces Advisory Fee Reduction and Update on Performance-Related Conditional Tender Offer

Business Wire

time01-07-2025

  • Business
  • Business Wire

Morgan Stanley China A Share Fund, Inc. Announces Advisory Fee Reduction and Update on Performance-Related Conditional Tender Offer

NEW YORK--(BUSINESS WIRE)--Morgan Stanley Investment Management announced today that, effective July 1, 2025, the annual advisory fee of Morgan Stanley China A Share Fund, Inc. (NYSE: CAF) (the 'Fund') will be reduced from an annual fee equal to 1.25% to an annual fee equal to 1.15% of the Fund's average weekly net assets. In addition, the requirements of the Fund's conditional tender offer announced on June 10, 2022 have not been met. Accordingly, the Fund will not be conducting a tender offer at this time, As was previously announced, the Board of Directors of the Fund approved a performance-related conditional tender offer to acquire in exchange for cash up to 25 percent of the Fund's then issued and outstanding shares at a price equal to 98.5 percent of the Fund's net asset value per share ('NAV') (minus the costs and expenses related to the tender offer) as of the close of regular trading on the New York Stock Exchange ('NYSE') on the business day the offer expires (a 'Tender Offer'). As explained in such prior announcement, the Fund would conduct such a Tender Offer only if both (1) the Fund's total return investment performance measured on a NAV basis did not equal or exceed the total return investment performance of the Fund's benchmark index, the MSCI China A Onshore Index, during the three-year period commencing on July 1, 2022 and ending on June 30, 2025 (and for the term of successive five-year periods thereafter commencing July 1, 2025), and (2) the Fund's shares were trading at or below NAV at the conclusion of the applicable measurement period, with such Tender Offer occurring on or before September 30, 2025, and thereafter on each five-year anniversary of September 30, 2025. For the period July 1, 2022 through June 30, 2025, the Fund's total return investment performance measured on a NAV basis exceeded that of the MSCI China A Onshore Index. As noted in the fund documents, performance assumes that all dividends and distributions, if any, were reinvested at prices obtained under the Fund's dividend reinvestment plan. 1 Accordingly, no Tender Offer will be conducted for this period. The conditions triggering a Tender Offer (as described above) will be assessed again at the conclusion of the five-year period commencing July 1, 2025 and ending on June 30, 2030 (and for successive five-year periods thereafter commencing on July 1, 2030). If a Tender Offer is triggered, the Fund will issue a press release announcing the Tender Offer and providing additional information about such Tender Offer. Additional terms and conditions of a Tender Offer would also be set forth in the relevant offering materials, which would be distributed to the Fund's shareholders. The size of any such Tender Offer (up to 25 percent of the Fund's then issued and outstanding shares), the price at which shares are to be tendered and other terms and conditions of such Tender Offer would be determined by the Board of Directors in its discretion based on its review and consideration of the then-current size of the Fund, market conditions, the ability to repatriate the necessary cash and subject to local Chinese regulatory requirements and other factors it deems relevant. In the event that a Tender Offer is triggered and more than 25 percent of the Fund's then issued and outstanding shares are tendered, the Fund will purchase its shares from tendering shareholders on a pro rata basis (odd-lot tenders for stockholders who own fewer than 100 shares are still subject to pro ration), based on the number of tendered shares, at a price equal to 98.5 percent of the Fund's NAV (minus the costs and expenses related to the tender offer), as described above. The Fund continues to maintain a share repurchase program (the 'Program') for purposes of enhancing stockholder value by providing the ability to repurchase shares at a discount to NAV. During the year ended December 31, 2024, the Fund repurchased 192,335 of its shares at an average discount of 18.21% from NAV. Since the inception of the Program, the Fund has repurchased (as of December 31, 2024) 362,922 of its shares at an average discount of 18.83% from NAV. The Board of Directors regularly monitors the Program as part of its review and consideration of the Fund's premium/discount history. The Fund may only repurchase its outstanding shares at such time and in such amounts as it believes will further the accomplishment of the foregoing objectives of the Program, subject to review by the Board of Directors and the Fund's ability to repatriate capital gains and income out of China. Upon commencement of a Tender Offer, the Fund expects to temporarily suspend any purchases of shares in the open market pursuant to the Program until at least 10 business days after the termination of the Tender Offer, as required by the Securities Exchange Act of 1934, as amended. The Fund is a non-diversified, closed-end management investment company that seeks capital growth by investing, under normal circumstances, at least 80% of its assets in A-shares of Chinese companies listed on the Shanghai and Shenzhen Stock Exchanges. The Fund's shares are listed on the NYSE under the symbol 'CAF'. About Morgan Stanley Investment Management Morgan Stanley Investment Management, together with its investment advisory affiliates, has more than 1,400 investment professionals around the world and $1.6 trillion in assets under management or supervision as of March 31, 2025. Morgan Stanley Investment Management strives to provide outstanding long-term investment performance, service and a comprehensive suite of investment management solutions to a diverse client base, which includes governments, institutions, corporations and individuals worldwide. For further information about Morgan Stanley Investment Management, please visit About Morgan Stanley Morgan Stanley is a leading global financial services firm providing investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm's employees serve clients worldwide including corporations, governments, institutions and individuals. For more information about Morgan Stanley, please visit This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful under the securities laws of any such state. Morgan Stanley Investment Management does not provide tax advice. Investors should always consult a legal or tax professional for information concerning their individual situation. Investing involves risk and it is possible to lose money on any investment in the Funds. 1 The Fund's Dividend Reinvestment Plan provides that if net asset value exceeds the market price on the reinvestment date, participants will receive shares valued at market price.

Two biopharma stocks to consider outside of Moderna
Two biopharma stocks to consider outside of Moderna

Yahoo

time02-06-2025

  • Business
  • Yahoo

Two biopharma stocks to consider outside of Moderna

Moderna (MRNA) shares are seeing a boost on Monday after the US Food and Drug Administration (FDA) gave the pharmaceutical giant limited approval for its lower-dose COVID-19 vaccine. Morgan Stanley Investment Management portfolio manager Jason Kritzer shares his perspective on the pharmaceutical industry amid pushback from the Trump administration's Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. Kritzer also weighs in on pet drug manufacturer Zoetis (ZTS). To watch more expert insights and analysis on the latest market action, check out more Catalysts here. Moderna shares moving to the upside today, the FDA granting the company limited approval for its lower dose COVID-19 vaccine. This coming as the pharmaceutical industry has been under pressure, facing fractured relationship with HHS head RFK Jr., as well as tariff policy risks more broadly. Our next guest names two key areas of opportunity for investors in the healthcare space. Joining us now, Jason Kreitzer, Morgan Stanley Investment Management portfolio manager. Jason, great to speak with you this morning. Obviously, as we mentioned, a lot of headwinds for the pharmaceutical industry. What is giving you some optimism about how pharma stocks could do in the second half of the year right now? Sure. Well, we're we're trying to focus on areas where there's less attention that the administration has. Uh, medical devices and animal health are two areas that uh, really are kind of avoiding a lot of the spotlight, uh, from an administration perspective. Um, you know, if you look at healthcare, it's been very, very volatile this year. Uh, bottom of the leaderboard, uh, in terms of performance in the S&P from the S&P sector perspective. So, uh, trying to find areas where, uh, there are opportunities. On the medical device side, we're we really like, uh, Intuitive Surgical. This is a robotic surgery company. Uh, this is a very cool company that it's um, very uh, innovative in terms of its, uh, uh, design of its new products which are helping surgeons basically become better, better at their job. Uh, the addressable market for the uh, for the Da Vinci five, which is their new, uh, their new robot, it's had about eight million global procedures. Uh, and this is in neurology, general surgery, gynecology. The company's procedure growth is in the 13 to 16% range. That's volume growth. We don't really see that kind of growth in uh, in healthcare and so this has been a terrific long-term compounder. Um, you know, in the other areas, uh, we really like uh, animal health. Um, Zoetus is a uh, leader in uh, in the both companion animal, which is pet and livestock space. Um, for the last 10 years, Zoetus has grown above market. And that has been um, a core to that thesis, really has been their innovation. They're very large in uh, pain, in flea and tick and uh, also in dermatology. Pain is more recently. Uh, there are 27 million dogs under the care of uh, vets in the US that have um, osteoarthritis and their pain medicine is uh, really just scratching the surface. They're only uh, attributed uh, sales that space to about a million dogs. Yeah. been a lot of questions in the uh, in the market about, uh, uh, drug pricing uh, in human health. Um, keep in mind, there's no Medicare. There's no doggy Medicare, so from that perspective, uh, you know, we like animal health. Yeah, I thought that was a really interesting framework, Jason. Is animal health investing a way to be Washington-proofing your health portfolio right now? We think so. We think so. I mean, you know, really, if you look at, it's a cash pay market. As I mentioned, no Medicare. Um, as we all know, people love their pets and will be, uh, willing to spend a lot on their pets sort of out of pocket. And so while no, uh, sector is completely immune to economic, uh, uncertainties, uh, the pet market is, is one that's, you know, very exciting. And my guest host, Jay Woods, has a question for you, Jason. Hey Jason, I I think you're on to something big there. The ETF pause, PAWZ is a conglomerate of all those uh, stocks. And you mentioned Zoetis, you may have already answered most of this question, but why does that stand out? Uh, because there are other options within the pet insurance sector. Uh, was it the livestock side of it? What was the thing that stuck out the most to you about Zoetis? Well, if you think about uh, Zoetis, Zoetis was a was a spin about uh, 12 years ago out of Pfizer. And their roots are really in on the innovation side on the animal health rather than on the livestock. They do, they are a leader in livestock. Um, and so their, uh, innovation engine is really what's attractive. They are coming out with new medicines for pets that um, have um, great outcomes. And that is really fueling their growth and you know, they're an above market grower, um, which has made it uh, attractive to us. Jason, really appreciate your time this morning. Thank you so much. Thank you. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store